No Data
No Data
No Data
No Data
No Data
Sensei Biotherapeutics to Present Topline Clinical Data From the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeut
GlobeNewswireApr 24 16:05 ET
12 Health Care Stocks Moving In Monday's After-Market Session
GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to
BenzingaApr 22 16:31 ET
Sensei Biotherapeutics Extends Relationship With Former CFO
TipRanksApr 12 16:43 ET
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today
GlobeNewswireApr 9 07:30 ET
Express News | Sensei Biotherapeutics Shares Are Trading Higher After the Company Announced the Publication of a Peer-reviewed Research Paper in Nature Communications the Described the Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA Within
Moomoo 24/7Apr 4 16:14 ET
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA Within the Tumor Microenvironment
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced the publication of a peer-reviewed research paper in Nature Communications.
GlobeNewswireApr 4 16:05 ET
Trytosaveabit : Well data is expected before the end of Q2. FDA meeting should be before EOY! It’s been on a decent uptrend for a while now! And the daily chart shows it may continue? GL
No Data
No Data